• Celcuity presented updated Phase 1b/2 results for gedatolisib with darolutamide in metastatic castration-resistant prostate cancer at ESMO on October 23, 2026.
• Patients previously treated with abiraterone had longer disease control than those previously treated with enzalutamide.
• The combination showed manageable safety, with no treatment-related discontinuations or deaths.
• Phase 2 is expected to begin in the first half of 2027 to determine the recommended Phase 3 dose.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Celcuity Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610230915PRIMZONEFULLFEED9851888) on October 23, 2026, and is solely responsible for the information contained therein.